The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Boston Pharmaceuticals
Stock and Other Ownership Interests - Boston Pharmaceuticals
 
Employment - Boston Pharmaceuticals
Honoraria - Boston Pharmaceuticals
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.
 
Patrick Schoffski
Honoraria - Blueprint Medicines; Boehringer Ingelheim; Deciphera
Consulting or Advisory Role - Adaptimmune (Inst); Advanced Medical (Inst); Blueprint Medicines; Blueprint Medicines (Inst); Boehringer Ingelheim; Deciphera; Ellipses Pharma; Ellipses Pharma (Inst); Exelixis; Guided Clarity; Intellisphere (Inst); Medscape; Transgene; Transgene (Inst); Ysios Capital
Research Funding - CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Ipsen (Inst); MSD (Inst)
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Oscotec; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Antoine Italiano
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; MSD; Roche
 
Herbert H. F. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Genentech; Ipsen; Janssen; Lilly; MedImmune; MSD; Novartis; Orion; Pfizer; Roche; Sanofi
 
Laura Medina Rodriguez
No Relationships to Disclose
 
Jin-Yuan Shih
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Research Funding - Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Chugai Pharma; Pfizer; Roche
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Loic Verlingue
Consulting or Advisory Role - Adaptherapy
Research Funding - Bristol-Myers Squibb
Other Relationship - Pierre Fabre; SERVIER
 
Karen Andreas
No Relationships to Disclose
 
Craig T. Basson
Employment - Boston Pharmaceuticals
Leadership - Boston Pharmaceuticals
Stock and Other Ownership Interests - Boston Pharmaceuticals
 
Alicia Clawson
Employment - Boston Pharmaceuticals
Stock and Other Ownership Interests - Boston Pharmaceuticals
 
Peter T.C. Ho
Employment - Boston Pharmaceuticals; Epizyme
Leadership - Boston Pharmaceuticals; Epizyme
Stock and Other Ownership Interests - Accent Therapeutics; Alcon; Asahi Kasei; AstraZeneca; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Daiichi Sankyo; Epizyme; Genmab; Johnson & Johnson; Merck; Merck KGaA; Novartis; Novo Nordisk; Novozymes; Otsuka; Pfizer; Qiagen; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Accent Therapeutics
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline - patent holder
 
Shelley Knight
Employment - Boston Pharmaceuticals
Stock and Other Ownership Interests - Boston Pharmaceuticals
 
Anita Scheuber
No Relationships to Disclose
 
Mitchell Keegan
Employment - Boston Pharmaceuticals
Stock and Other Ownership Interests - Boston Pharmaceuticals